Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 9, 2017 in Diabetes mellitus | 0 comments

In a nutshell

This study explored whether glucagon-like peptide-1 receptor agonists (GLP-1RAs) were effective in treating type-2 diabetes. The authors concluded that all GLP-1RA’s were effective and that the type of GLP-1RA chosen could be tailored to a patient’s specific needs.

Some background

Insulin is a hormone which controls blood-sugar levels. Patients with type-2 diabetes (T2D) do not produce enough insulin or are resistant to insulin. One potential treatment option are GLP-1RAs. Several GLP-1RAs exist, with varying effects. It is not clear whether one GLP-1RA is more effective than others.

Methods & findings

This study assessed the effectiveness of eight GLP-1RAs in controlling both blood sugar and other health factors (such as blood pressure and weight loss). It also assessed the potential side effects.

The results of 34 trials (including a total 14,464 patients) were analyzed. The GLP-1RAs included were either “short-acting” (twice-daily exenatide [Byetta] or lixisenatide [Adlyxin]) or “long-acting” (once-weekly liraglutide [Victoza]; albiglutide [Tanzeum]; dulaglutide [Trulicity]; exenatide [Bydureon]; semaglutide; and taspoglutide). The effects of these medicines were compared with a placebo (substance with no effect), as well as with each other.

There were no notable differences in effects between the two short-acting agents, as well as between the six long-acting agents. All GLP-1RAs reduced HbA1c (average blood glucose over 3 months) and fasting blood glucose (glucose levels after a period without food or drink) compared to placebo. All GLP-1RAs except for albiglutide also reduced weight and increased the risk of hypoglycemia (dangerously low blood pressure) compared to placebo. All GLP-1RAs (except dulaglutide and taspoglutide) decreased systolic blood pressure (the measure of blood flow as the heart contracts).

Three long-acting agents (dulaglutide, liraglutide and once-weekly exenatide) were significantly better at controlling blood glucose compared to twice-daily exenatideAlbiglutide was associated with the lowest risk of nausea and diarrhea. Once-weekly exenatide had the lowest risk of vomiting.

The bottom line

This study concluded that the GLP-1RAs reviewed were all effective at reducing blood sugar levels. The study also concluded that intensity of the potential side-effects (i.e. nausea, diarrhea, vomiting) varied depending on the type of GLP-1RA. 

The fine print

Taspoglutide is no longer under investigation, and will not be approved for use.

What’s next?

Consult your doctor about the best treatment option for you.

Published By :

Diabetes, Obesity and Metabolism

Date :

Dec 16, 2016

Original Title :

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes Systematic review and mixed-treatment comparison analysis.

click here to get personalized updates